MYASTHENIA gravis (MG) preferentially involves the ocular muscles.1 Ocular myasthenia manifests as weakness of the levator palpebrae superioris leading to ptosis, or the extraocular muscles producing diplopia. The precise reasons for this predilection are poorly understood.2,3 As with all therapies for MG, there are few well-controlled studies of treatments of ocular myasthenia.4 Immunosuppressive therapies, in particular the corticosteroid prednisone, are the mainstay of treatment for generalized MG that compromises an individual's daily activities. Prednisone is also commonly used for ocular myasthenia. However, 4 factors should be considered prior to the use of steroids for patients with MG isolated to the ocular muscles: (1) Could the patient's symptoms improve with safer forms of therapy? (2) Will steroid treatment lead to resolution of symptoms? (3) Does the severity of the symptoms warrant the risk of steroid adverse effects? (4) Do steroids reduce the chance of generalization? We consider each of these questions and reach the conclusion that only the occasional case of ocular myasthenia should be treated with steroids.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Neurology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 19
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.